Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Glaxosmithkline Consumer Nigeria Rises to Five-Month High

Don't Miss Out —
Follow us on:

June 27 (Bloomberg) -- GlaxoSmithKline Consumer Nigeria Plc, a unit of the U.K.’s biggest drugmaker, advanced for the first time in three days, closing at a five-month high.

The stock rose 2.2 percent to 23 naira by the close in Lagos, the commercial capital, its highest since Jan. 24.

“The company has a lot of ethical and common drugs that command a lot of patronage in the market,” Raheem Mohammed, chief operating officer of Kundila Finance Ltd., said by phone from Lagos today.

Glaxosmithkline plans to raise revenue by 25 percent this year as it expands sales of branded retail items, the company said on Feb. 21. Full-year profit rose 16 percent to 2.3 billion naira, ($14 million), the company said on March 15.

To contact the reporter on this story: Vincent Nwanma in Lagos at

To contact the editor responsible for this story: Dulue Mbachu at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.